Clinical Practice Session
Controversies in the Clinical Management of CKD-MBD
October 26, 2024 | 10:30 AM - 12:30 PM
Location: Room 7, Convention Center
Session Description
Our understanding of the pathogenesis and optimal treatment of CKD-MBD continues to evolve, and new developments are quickly incorporated into clinical practice. Optimal management, however, is not always apparent and expert opinion sometimes diverges. This session focuses on two recent controversies sparked by new data, with expert discussants presenting opposing viewpoints.
Learning Objective(s)
- Describe current serum phosphate targets in CKD and ESKD
- Identify systemic complications associated with hyperphosphatemia
- Contrast calcimimetics vs. vitamin D analogues as first-line therapy for secondary hyperparathyroidism
Learning Pathway(s)
- Bones‚ Stones‚ and Mineral Metabolism
- Dialysis
Moderators
Presentations
- To Treat or Not to Treat Hyperphosphatemia (to Target): Pro
10:30 AM - 11:00 AM
- To Treat or Not to Treat Hyperphosphatemia (to Target): Con
11:00 AM - 11:30 AM
- Who's on First? First-Line Treatment in Secondary Hyperparathyroidism in ESKD: Calcimimetics
11:30 AM - 12:00 PM
- Who's on First? First-Line Treatment in Secondary Hyperparathyroidism in ESKD: Vitamin D Analogues
12:00 PM - 12:30 PM